Accelerate Diagnostics Announces Final Results of Rights Offering

      Accelerate Diagnostics Announces Final Results of Rights Offering

PR Newswire

TUCSON, Ariz., Aug. 13, 2013

TUCSON, Ariz., Aug. 13, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc.
(NASDAQ: AXDX), announced today that it has completed its previously announced
rights offering. Through broad participation from both insiders and
non-insider investors, the Company raised $20,000,000, including proceeds from
a standby commitment made by Abeja Ventures, LLC.

Stockholders subscribed for a total of 1,871,410 shares of the Company's
common stock pursuant to their basic subscription privileges, representing a
75% participation rate. In addition, stockholders over subscribed for a total
of 1,077,471 shares of which 203,062 shares were issued following exclusions
based on the outcome of the basic subscription. Finally, a total of 413,090
shares of common stock will be issued to the standby purchaser. In the
aggregate, the Company will issue 2,487,562 shares of common stock of which
1,719,425 shares, or 69%, were acquired by directors of the company.

"The broad participation of our directors and general shareholder base in this
offering underscores the great ongoing support for the company, our
technology, and its market potential," said Lawrence Mehren, CEO of Accelerate
Diagnostics, Inc.

The shares of the Company's common stock issuable pursuant to the rights
offering and Standby Purchase Agreement will be issued to stockholders and the
standby purchaser as promptly as practicable.

The rights offering was made pursuant to a Registration Statement on Form S-3
that was filed with the Securities and Exchange Commission (SEC) and became
effective on July 12, 2013. The rights offering was made solely by means of
the prospectus that was filed with the SEC on July 12, 2013.For questions
about the rights offering, contact Broadridge Corporate Issuer Solutions, Inc.
at (855) 793-5068. Broadridge acted as the Subscription and Information Agent
for the rights offering on behalf of the Company.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in-vitro diagnostics company
focused on developing and commercializing innovative systems for the rapid
identification and antibiotic susceptibility testing of infectious pathogens.
The Company's revolutionary BACcel™ platform utilizes a proprietary
culture-free process with both genomic and phenotypic detection technologies
that significantly decreases time to result while achieving high sensitivity
and specificity. In addition to the BACcel system development pipeline, the
Company also owns and licenses its proprietary OptiChem™ surface coatings
technology, which has numerous applications for binding in bio-analytical
systems, such as microarrays. For more information, visit:
www.acceleratediagnostics.com.

Forward-Looking Statements
This press release contains words such as "expects," "shall," "will,"
"believes" and other similar expressions that are intended to identify
forward-looking statements within the meaning of the Safe Harbor Provisions of
the Private Securities Litigation Reform Act of 1995. Such statements in this
announcement are made based on the Company's current beliefs, known events and
circumstances at the time of publication and, as such, are subject in the
future to unforeseen risks and uncertainties that could cause the Company's
results of operations, performance and achievements to differ materially from
current expectations expressed in, or implied by, these forward-looking
statements. For a full discussion of the Company's risks and uncertainties,
which could cause actual results to differ from those contained in the
forward-looking statements, see "Risk Factors" in Item 1A in the Company's
Transition Report on Form 10-KT, filed with the SEC on March 20, 2013. In
addition, the Company's forward-looking statements could be affected by
general industry and market conditions and growth rates. Except as required by
federal securities laws, the Company undertakes no obligation to update or
revise these forward-looking statements to reflect new events, uncertainties
or other contingencies.



SOURCE Accelerate Diagnostics, Inc.

Website: http://acceleratediagnostics.com
 
Press spacebar to pause and continue. Press esc to stop.